Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
MO43110
Phase 3 small_molecule completed
Quick answer
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC) for Early Breast Cancer is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Early Breast Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed